{
    "organizations": [],
    "uuid": "f6344aa610102af020a52885c09bd76015941605",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aeglea-biotherapeutics-qtrly-loss/brief-aeglea-biotherapeutics-qtrly-loss-per-share-0-49-idUSASC0A0GA",
    "ord_in_thread": 0,
    "title": "BRIEF-Aeglea Biotherapeutics Qtrly Loss Per Share $0.49",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Aeglea Bio Therapeutics Inc:\n* AEGLEA BIOTHERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* QTRLY LOSS PER SHARE $0.49 * AS OF MARCH 31, 2018, AEGLEA HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $43.5 MILLION\n* CO BELIEVES IT HAS SUFFICIENT CAPITAL RESOURCES TO FUND ANTICIPATED OPERATIONS THROUGH THE MIDDLE OF 2020 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-08T20:15:00.000+03:00",
    "crawled": "2018-05-09T12:23:59.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "aeglea",
        "bio",
        "therapeutic",
        "inc",
        "aeglea",
        "biotherapeutics",
        "provides",
        "corporate",
        "update",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "qtrly",
        "loss",
        "per",
        "share",
        "march",
        "aeglea",
        "available",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "million",
        "co",
        "belief",
        "sufficient",
        "capital",
        "resource",
        "fund",
        "anticipated",
        "operation",
        "middle",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}